User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO)

Primary tabs

download
  • Open access
  • PDF
  • 56.28 K
Ferrara, R. Naigeon, M. Auclin, E. Duchemann, B. Cassard, L. Aboubakar Nana, Frank [UCL] Chaput, N.

BACKGROUND: iSenescence is a progressive remodeling of immune functions with a multifactorial etiology (i.e. aging, chronic inflammation, cancer). Although the absence of CD28 and the expression of CD57 and Killer-cell lectin-like receptor G1 (KLRG1) on peripheral T-lymphocytes are potential hallmarks of iSenescence, the characterization of such phenotype in IO-treated aNSCLC patients and the correlation with clinical characteristics and benefit from immunotherapy are currently unknown. [...]

Document type Communication à un colloque (Conference Paper) – Poster, Abstract
Access type Accès libre
Publication date 2018
Language Anglais
Conference "43rd ESMO Congress (ESMO 2018)", (Germany) Munich (du 19/10/2018 au 23/10/2018)
Journal information "Annals of Oncology" - Vol. 29, no.Suppl 8, p. viii511 (2018)
Peer reviewed yes
issn 0923-7534
e-issn 1569-8041
Publisher Elsevier ((United Kingdom) London)
Publication status Publié
Affiliations UCL - SSS/IREC/LUNS - Pôle pneumologie, ORL (airways) et dermatologie (skin)
UCL - (SLuc) Service de pneumologie
Keywords Oncology ; Hematology
Links
Bibliographic reference Ferrara, R. ; Naigeon, M. ; Auclin, E. ; Duchemann, B. ; Cassard, L. ; et. al. Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO).43rd ESMO Congress (ESMO 2018) ((Germany) Munich, du 19/10/2018 au 23/10/2018). In: Annals of Oncology, Vol. 29, no.Suppl 8, p. viii511 (2018)
Permanent URL http://hdl.handle.net/2078.1/240589